Display options
Cite
Legatowicz-Koprowska M, Nitek S, Czerwińska J. The complement system in primary Sjögren's syndrome: the expression of certain cascade and regulatory proteins in labial salivary glands - observational study. Reumatologia. 2020;58(6):357-366doi: 10.5114/reum.2020.102000.
Legatowicz-Koprowska, M., Nitek, S., & Czerwińska, J. (2020). The complement system in primary Sjögren's syndrome: the expression of certain cascade and regulatory proteins in labial salivary glands - observational study. Reumatologia, 58(6), 357-366. https://doi.org/10.5114/reum.2020.102000
Legatowicz-Koprowska, Marta, et al. "The complement system in primary Sjögren's syndrome: the expression of certain cascade and regulatory proteins in labial salivary glands - observational study." Reumatologia vol. 58,6 (2020): 357-366. doi: https://doi.org/10.5114/reum.2020.102000
Legatowicz-Koprowska M, Nitek S, Czerwińska J. The complement system in primary Sjögren's syndrome: the expression of certain cascade and regulatory proteins in labial salivary glands - observational study. Reumatologia. 2020;58(6):357-366. doi: 10.5114/reum.2020.102000. Epub 2020 Dec 23. PMID: 33456078; PMCID: PMC7792541.
Copy Download .nbib Format: NLM
Share it on

Reumatologia. 2020;58(6):357-366. doi: 10.5114/reum.2020.102000. Epub 2020 Dec 23.

The complement system in primary Sjögren's syndrome: the expression of certain cascade and regulatory proteins in labial salivary glands - observational study.

Reumatologia

Marta Legatowicz-Koprowska, Stanisław Nitek, Jolanta Czerwińska

Affiliations

  1. Department of Pathology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
  2. Department of Otolaryngology, Medical University of Warsaw, Poland.

PMID: 33456078 PMCID: PMC7792541 DOI: 10.5114/reum.2020.102000

Abstract

INTRODUCTION: The complement cascade and regulatory proteins are involved in the pathogenesis of the Sjögren's syndrome and other autoimmune diseases. The complement activation via the alternative pathway was recognized as a major pathogenic mechanism in autoimmune conditions. The aim of this study was to assess expression of complement cascade components and regulatory proteins in minor salivary glands in patients with primary Sjögren's syndrome (pSS).

MATERIALS AND METHODS: The expression of C1q and C5b-9 - membrane attack complex and regulatory proteins such as: membrane cofactor protein (MCP), decay-accelerating factor (DAF) and protectin were examined using immunochemistry method in specimens from biopsy of minor salivary glands in pSS patients. The biopsy material was obtained from 20 pSS patients, 5 patients with non-specific sialadenitis and from 5 patients with suspicion of dryness syndrome without sialadenitis confirmation.

RESULTS: None of the examined samples showed the expression of C1q or the effector C5b-9. Membrane cofactor protein expression was lower in pSS group than in both non-specific sialadenitis and noninflamed salivary glands. The inflammatory cells in pSS samples partially expressed MCP. There were differences in the sites and intensity of membrane protectin expression exclusively on the luminal surfaces in pSS; on the luminal and, partially, antiluminal surface in non-specific inflammation, and on the entire cell surface in unaffected salivary glands. There were no DAF expression in salivary gland tissue in biopsy specimens in all studied subjects.

CONCLUSIONS: The study demonstrated the absence of complement-cascade proteins (C1q, MAC) in the salivary glands of pSS patients, which may indicated a lack of local complement activation via the classical pathway and the observed gland tissue damage being due to a mechanism other than MAC-induced cytolysis. The differences in the expression of complement regulatory proteins between pSS, non-specific sialadenitis, and normal salivary glands may indicate that alternative functions of these regulatory proteins may be of greater significance in pSS. Low MCP expression in pSS in comparison with non-specific sialadenitis and normal salivary glands, may suggest altered modulation of cell-mediated immunity in pSS. The differences in the location and intensity of protectin (CD59) expression indicates a possibility of reducing the proinflammatory effect of protectin in pSS.

Copyright: © 2020 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie.

Keywords: complement system proteins; membrane cofactor protein CD46; primary Sjogren’s syndrome; protectin CD59

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):105-17 - PubMed
  2. J Clin Exp Dent. 2017 Apr 1;9(4):e584-e589 - PubMed
  3. Eur J Immunol. 2003 Dec;33(12):3367-76 - PubMed
  4. Autoimmun Rev. 2012 Feb;11(4):281-7 - PubMed
  5. Immunology. 1993 Jul;79(3):341-7 - PubMed
  6. Mol Immunol. 2007 Jan;44(1-3):73-81 - PubMed
  7. Scand J Immunol. 1995 Apr;41(4):350-6 - PubMed
  8. N Engl J Med. 2001 Apr 5;344(14):1058-66 - PubMed
  9. Immune Netw. 2018 Feb 20;18(1):e11 - PubMed
  10. Nature. 2003 Jan 23;421(6921):388-92 - PubMed
  11. Blood. 1990 Jan 1;75(1):284-9 - PubMed
  12. Arthritis Res Ther. 2006;8(4):R130 - PubMed
  13. J Autoimmun. 2010 May;34(3):J276-86 - PubMed
  14. J Immunol. 2006 Mar 1;176(5):2915-23 - PubMed
  15. Lab Invest. 1992 Nov;67(5):608-16 - PubMed
  16. Mol Immunol. 2015 Feb;63(2):176-83 - PubMed
  17. Clin Immunol. 2006 Feb-Mar;118(2-3):127-36 - PubMed
  18. Arch Immunol Ther Exp (Warsz). 2009 Nov-Dec;57(6):393-407 - PubMed
  19. Lupus. 2015 Mar;24(3):315-20 - PubMed
  20. Rheumatology (Oxford). 2005 Jan;44(1):89-94 - PubMed
  21. Ann Rheum Dis. 1996 Dec;55(12):888-94 - PubMed
  22. Arthritis Rheum. 2010 Apr;62(4):1036-42 - PubMed
  23. Nat Rev Rheumatol. 2010 Sep;6(9):529-37 - PubMed
  24. J Exp Med. 1987 Mar 1;165(3):848-64 - PubMed
  25. Clin Exp Rheumatol. 1997 Nov-Dec;15(6):615-23 - PubMed
  26. Arthritis Rheum. 2004 Sep;50(9):3035-44 - PubMed
  27. Autoimmun Rev. 2018 Mar;17(3):215-225 - PubMed
  28. Nat Immunol. 2004 Oct;5(10):981-6 - PubMed
  29. Arthritis Rheumatol. 2017 Jan;69(1):35-45 - PubMed
  30. Immunology. 2001 Oct;104(2):207-14 - PubMed
  31. Mol Immunol. 2004 Jun;41(2-3):147-52 - PubMed
  32. J Clin Lab Anal. 2018 Nov;32(9):e22585 - PubMed
  33. Lab Invest. 1991 Nov;65(5):532-7 - PubMed
  34. J Immunol. 2006 Jul 15;177(2):1070-7 - PubMed
  35. J Immunol. 1991 Jun 15;146(12):4092-8 - PubMed

Publication Types